» Articles » PMID: 30006541

Transcriptional Downregulation of MiR-133b by REST Promotes Prostate Cancer Metastasis to Bone Via Activating TGF-β Signaling

Overview
Journal Cell Death Dis
Date 2018 Jul 15
PMID 30006541
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

High avidity of bone metastasis is an important characteristic in prostate cancer (PCa). Downexpression of miR-133b has been reported to be implicated in the development, progression and recurrence in PCa. However, clinical significance and biological roles of miR-133b in bone metastasis of PCa remain unclear. Here we report that miR-133b is downregulated in PCa tissues and further decreased in bone metastatic PCa tissues. Downexpression of miR-133b positively correlates with advanced clinicopathological characteristics and shorter bone metastasis-free survival in PCa patients. Upregulating miR-133b inhibits invasion, migration in vitro and bone metastasis in vivo in PCa cells. Mechanistically, we find that miR-133b suppresses activity of TGF-β signaling via directly targeting TGF-β receptor I and II, which further inhibits bone metastasis of PCa cells. Our results further reveal that overexpression of REST contributes to miR-133b downexpression via transcriptional repression in PCa tissues. Importantly, silencing miR-133b enhances invasion and migration abilities in vitro and bone metastasis ability in vivo in REST-silenced PCa cells. The clinical correlation of miR-133b with TGFBRI, TGFBRII, REST and TGF-β signaling activity is verified in PCa tissues. Therefore, our results uncover a novel mechanism of miR-133b downexpression that REST transcriptionally inhibits miR-133b expression in PCa cells, and meanwhile support the notion that administration of miR-133b may serve as a rational regimen in the treatment of PCa bone metastasis.

Citing Articles

Bone metastases of prostate cancer: Molecular mechanisms, targeted diagnosis and targeted therapy (Review).

Guo X, Li S Oncol Rep. 2025; 53(4).

PMID: 39981932 PMC: 11865881. DOI: 10.3892/or.2025.8879.


The regulatory process and practical significance of non-coding RNA in the dissemination of prostate cancer to the skeletal system.

Sang H, Li L, Zhao Q, Liu Y, Hu J, Niu P Front Oncol. 2024; 14:1358422.

PMID: 38577343 PMC: 10991771. DOI: 10.3389/fonc.2024.1358422.


The Bone Microenvironment Soil in Prostate Cancer Metastasis: An miRNA Approach.

Prigol A, Rode M, da Luz Efe F, Saleh N, Creczynski-Pasa T Cancers (Basel). 2023; 15(16).

PMID: 37627055 PMC: 10452124. DOI: 10.3390/cancers15164027.


Animal models of cancer metastasis to the bone.

Yu Y, Li K, Peng Y, Wu W, Chen F, Shao Z Front Oncol. 2023; 13:1165380.

PMID: 37091152 PMC: 10113496. DOI: 10.3389/fonc.2023.1165380.


Forkhead box L2 is a target of miR-133b and plays an important role in the pathogenesis of non-small cell lung cancer.

Li J, Gao L, Wang A, Qian H, Zhu J, Ji S Cancer Med. 2023; 12(8):9826-9842.

PMID: 36846934 PMC: 10166978. DOI: 10.1002/cam4.5746.


References
1.
Li X, Wan X, Chen H, Yang S, Liu Y, Mo W . Identification of miR-133b and RB1CC1 as independent predictors for biochemical recurrence and potential therapeutic targets for prostate cancer. Clin Cancer Res. 2014; 20(9):2312-25. DOI: 10.1158/1078-0432.CCR-13-1588. View

2.
Kang Y, He W, Tulley S, Gupta G, Serganova I, Chen C . Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A. 2005; 102(39):13909-14. PMC: 1236573. DOI: 10.1073/pnas.0506517102. View

3.
Kreisler A, Strissel P, Strick R, Neumann S, Schumacher U, Becker C . Regulation of the NRSF/REST gene by methylation and CREB affects the cellular phenotype of small-cell lung cancer. Oncogene. 2010; 29(43):5828-38. DOI: 10.1038/onc.2010.321. View

4.
Qin W, Dong P, Ma C, Mitchelson K, Deng T, Zhang L . MicroRNA-133b is a key promoter of cervical carcinoma development through the activation of the ERK and AKT1 pathways. Oncogene. 2011; 31(36):4067-75. DOI: 10.1038/onc.2011.561. View

5.
Chan M, Liaw C, Ji S, Tan H, Wong C, Thike A . Identification of circulating microRNA signatures for breast cancer detection. Clin Cancer Res. 2013; 19(16):4477-87. DOI: 10.1158/1078-0432.CCR-12-3401. View